Long-acting Basal Insulin Controls A1C as Well as Glargine

Key clinical point: In patients with type 1 diabetes, treatment with the long-acting basal insulin peglispro conferred lower HbA_1c with fewer episodes of nocturnal hypoglycemia – and weight loss as well.

Major finding: At 26 weeks, HbA_1c was significantly lower in those taking BIL than GL (7% vs. 7.4%).

Data source: The open-label IMAGINE 1 study comprised 455 patients.

Disclosures: Eli Lilly & Co. funded the study. Dr. Garg has received research funding from the company.